Free Standard AU & NZ Shipping For All Book Orders Over $80!
Register      Login
Journal of Primary Health Care Journal of Primary Health Care Society
Journal of The Royal New Zealand College of General Practitioners
RESEARCH ARTICLE (Open Access)

Avoiding acute kidney injury in primary care: attitudes and behaviours of general practitioners and community pharmacists in Hawke’s Bay

Dianne Vicary 1 4 , Colin Hutchison 2 , Trudi Aspden 3
+ Author Affiliations
- Author Affiliations

1 Vicary Pharmacy Services Limited, Napier, New Zealand

2 Hawke’s Bay District Health Board, Hastings, New Zealand

3 School of Pharmacy, University of Auckland, Auckland, New Zealand

4 Corresponding author. Email: dianne.vicary@xtra.co.nz

Journal of Primary Health Care 12(3) 244-256 https://doi.org/10.1071/HC19106
Published: 22 September 2020

Journal Compilation © Royal New Zealand College of General Practitioners 2020 This is an open access article licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

Abstract

INTRODUCTION: Awareness of the effect of acute kidney injury on patient outcomes and health systems is growing internationally. New Zealand’s approach focuses on stopping consumption of ‘at-risk’ medicines when acute kidney injury has been established and raising awareness of the risks associated with the Triple Whammy drug combination.

AIM: To explore current practices and views of Hawke’s Bay general practitioners (GPs) and community pharmacists regarding patient education about medicines with potential for contributing to community-acquired acute kidney injury, with a focus on community pharmacists providing patient education regarding when to temporarily withhold ‘at-risk’ medicines during acute dehydrating illnesses.

METHODS: Two tailored cross-sectional online anonymous surveys of GPs and community pharmacists working in Hawke’s Bay were administered between 2015 and 2016. Descriptive statistics were generated from the closed-question responses and manifest content analysis was applied to the free-text responses.

RESULTS: Twenty-two percent (37/167) of GPs and 34% (32/95) of pharmacists responded. Most respondents, GPs (34/37) and pharmacists (25/32), self-reported expertise to educate patients on temporarily withholding ‘at-risk’ medicines during acute dehydrating illnesses. Twenty-nine (78%) GPs had confidence in pharmacists providing this patient education and 20 (54%) welcomed pharmacist contact regarding a Triple Whammy prescription. However, for a variety of reasons, pharmacists did not routinely provide this education or contact GPs.

DISCUSSION: Both GPs and community pharmacists reported they had expertise to provide useful patient education about ‘at-risk’ medicine use during acute dehydrating illnesses. Dialogue to clarify the role of the two groups would be beneficial to achieve a more coordinated approach to patient care. Relevant strategies and frameworks already exist, but national interprofessional leadership and local application would be beneficial.

Keywords: General Practitioners; pharmacy services; primary health care; counselling practice


References

[1]  Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012; 2 1–138.

[2]  Wang X, Bonventre JV, Parrish AR. The aging kidney: increased susceptibility to nephrotoxicity. Int J Mol Sci. 2014; 15 15358–76.
The aging kidney: increased susceptibility to nephrotoxicity.Crossref | GoogleScholarGoogle Scholar | 25257519PubMed |

[3]  National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. NICE guideline [NG148]. London: NHS England; 2019. [cited 2020 April 18]. Available from: https://www.nice.org.uk/guidance/ng148

[4]  Selby NM, Crowley L, Fluck RJ,, et al. Use of electronic results reporting to diagnose and monitor AKI in hospitalized patients. Clin J Am Soc Nephrol. 2012; 7 533–40.
Use of electronic results reporting to diagnose and monitor AKI in hospitalized patients.Crossref | GoogleScholarGoogle Scholar | 22362062PubMed |

[5]  Dasta JF, Kane-Gill S. Review of the literature on the costs associated with Acute Kidney Injury. J Pharm Pract. 2019; 32 292–302.
Review of the literature on the costs associated with Acute Kidney Injury.Crossref | GoogleScholarGoogle Scholar | 31291842PubMed |

[6]  Royal Pharmaceutical Society & Centre for Pharmacy Postgraduate Education. Medicines optimisation briefing. London: Royal Pharmaceutical Society & Centre for Pharmacy Postgraduate Education; 2015. [cited 2020 June 22]. Available from: https://www.cppe.ac.uk/wizard/files/news%20attachments/aki_mo_briefing_final.pdf

[7]  Diabetes Canada Clinical Practice Guidelines Expert Committee Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018; 42 S1–S325.
| 29650079PubMed |

[8]  NHS Scotland. Medicines Sick Day Rules Card. Edinburgh: The Improvement Hub: Healthcare Improvement Scotland, 2020. [cited 2020 June 27]. Available from: https://ihub.scot/improvement-programmes/scottish-patient-safety-programme-spsp/spsp-medicines-collaborative/high-risk-situations-involving-medicines/medicines-sick-day-rules-card/

[9]  Huerta C, Castellsagué J, Varas-Lorenzo C, García Rodríguez LA. Non-steroidal anti-inflammatory drugs and risk of AFR in the general population. Am J Kidney Dis. 2005; 45 531–9.
Non-steroidal anti-inflammatory drugs and risk of AFR in the general population.Crossref | GoogleScholarGoogle Scholar | 15754275PubMed |

[10]  Lapi F, Azoulay L, Yin H, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013; 346 e8525
Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study.Crossref | GoogleScholarGoogle Scholar | 23423367PubMed |

[11]  Camin RMG, Cols M, Chevarria JL, et al. Acute kidney injury secondary to a combination of rennin-angiotensin system inhibitors, diuretics and NSAIDS. “The Triple Whammy”. Nefrologia. 2015; 35 197–206.
Acute kidney injury secondary to a combination of rennin-angiotensin system inhibitors, diuretics and NSAIDS. “The Triple Whammy”.Crossref | GoogleScholarGoogle Scholar |

[12]  Health Quality & Safety Commission. Over 22,000 NZers at risk of kidney harm because of medicine ‘triple whammy’. Wellington: Health Quality & Safety Commission New Zealand; 2017. [cited 2020 June 6]. Available from: https://www.hqsc.govt.nz/news-and-events/news/3101/

[13]  Medsafe Pharmacovigilance Team NSAIDS and acute kidney injury. Prescriber Update. 2013; 34 14–5.

[14]  Medsafe Pharmacovigilance Team Acute kidney injury - dangerous to continue some medicines. Prescriber Update. 2014; 35 9–10.

[15]  Best Practice Advocacy Centre New Zealand. Avoiding the triple whammy in primary care: ace inhibitors / ARB + diuretic + NSAID. Dunedin: Best Practice Advocacy Centre New Zealand; 2018. [cited 2020 March 7]. Available from: https://bpac.org.nz/2018/docs/triple-whammy.pdf

[16]  Pharmacy Council of New Zealand. Code of Ethics. Wellington: Pharmacy Council of New Zealand; 2018. [cited 2018 September 14]. Available from: https://www.pharmacycouncil.org.nz/Portals/12/Documents/standardsguidelines/Code%20of%20Ethics%202018%20FINAL.pdf?ver=2018-03-04-215933-993

[17]  Ministry of Health. Pharmacy Action Plan 2016 to 2020. Wellington: Ministry of Health; 2016. [cited 2020 June 22]. Available from: https://www.health.govt.nz/publication/pharmacy-action-plan-2016-2020

[18]  Pai AB. Keeping kidneys safe: the pharmacist’s role in NSAID avoidance in high-risk patients. J Am Pharm Assoc. 2015; 55 e15–e25.
Keeping kidneys safe: the pharmacist’s role in NSAID avoidance in high-risk patients.Crossref | GoogleScholarGoogle Scholar |

[19]  Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today. 2004; 24 105–12.
Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness.Crossref | GoogleScholarGoogle Scholar | 14769454PubMed |

[20]  Bengtsson M. How to plan and perform a qualitative study using content analysis. NursingPlus Open. 2016; 2 8–14.
How to plan and perform a qualitative study using content analysis.Crossref | GoogleScholarGoogle Scholar |

[21]  Think Kidneys Board. “Sick day” guidance in patients at risk of Acute Kidney Injury: position statement. Bristol: UK Renal Registry; 2020. [cited 2020 February 24]. Available from: https://www.thinkkidneys.nhs.uk/aki/wp-content/uploads/sites/2/2020/01/2020-AKI-Sick-Day-Guidance-Think-Kidneys.pdf

[22]  Whiting P, Morden A, Tomlinson LA, et al. What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis. BMJ Open. 2017; 7 e012674
What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar | 28389482PubMed |

[23]  Morris RL, Ashcroft D, Phipps D, et al. Preventing acute kidney injury: a qualitative study exploring ‘sick day rules’ implementation in primary care. BMC Fam Pract. 2016; 17 91
Preventing acute kidney injury: a qualitative study exploring ‘sick day rules’ implementation in primary care.Crossref | GoogleScholarGoogle Scholar | 27449672PubMed |

[24]  Martindale AM, Elvey R, Howard SJ, et al. Understanding the implementation of ‘sick day guidance’ to prevent acute kidney injury across a primary care setting in England: a qualitative evaluation. BMJ Open. 2017; 7 e017241
Understanding the implementation of ‘sick day guidance’ to prevent acute kidney injury across a primary care setting in England: a qualitative evaluation.Crossref | GoogleScholarGoogle Scholar | 29122792PubMed |

[25]  Hatah E, Braund R, Duffull S, Tordoff J. General practitioners’ perceptions of pharmacists’ new services in New Zealand. Int J Clin Pharm. 2012; 34 364–73.
General practitioners’ perceptions of pharmacists’ new services in New Zealand.Crossref | GoogleScholarGoogle Scholar | 22359183PubMed |

[26]  Pharmacy Council of New Zealand. Medicines management: definition, levels, competence framework. Wellington: Pharmacy Council of New Zealand; 2006. [cited 2020 June 22]. Available from: https://www.pharmacycouncil.org.nz/dnn_uploads/Documents/standardsguidelines/PCNZ%20MedMgmtCompFramework%20Oct%2009.pdf?ver=2017-02-20-105111-513

[27]  Bryant L, Maney J, Martini N. Changing perspectives of the role of community pharmacists: 1998 – 2012. J Prim Health Care. 2017; 9 34–46.
Changing perspectives of the role of community pharmacists: 1998 – 2012.Crossref | GoogleScholarGoogle Scholar | 29530186PubMed |

[28]  Bidwell S, Thompson L. GPs, community pharmacists and shifting professional boundaries. N Z Med J. 2015; 128 19–26.
| 26117387PubMed |

[29]  Mullan J, Weston K, Bonney A, et al. Consumer knowledge about over-the-counter NSAIDs: they don’t know what they don’t know. Aust N Z J Public Health. 2017; 41 210–4.
Consumer knowledge about over-the-counter NSAIDs: they don’t know what they don’t know.Crossref | GoogleScholarGoogle Scholar | 27774735PubMed |

[30]  Centre for Pharmacy Postgraduate Education. Acute kidney injury. Manchester, UK: The University of Manchester; 2018. [cited 2018 September 14]. Available from: https://www.cppe.ac.uk/programmes/l/kidneydl-p-01/

[31]  National Institute of Diabetes and Digestive and Kidney Diseases. Counselling patients on NSAID use to prevent kidney injury - Continuing Education Program. London: National Institutes of Health; 2014. [cited 2020 June 22]. Available from: https://www.niddk.nih.gov/health-information/professionals/education-cme/counseling-patients-nsaid-use?dkrd=hisce0082

[32]  Pharmaceutical Society of New Zealand and New Zealand Medical Association. An integrated framework for pharmacists and doctors. Wellington: Pharmaceutical Society of New Zealand and New Zealand Medical Association; 2017. [cited 2020 June]. Available from: https://www.psnz.org.nz/Folder?Action=View%20File&Folder_id=96&File=IntegratedHealthCareFramework_Final.pdf

[33]  Pharmacy Council of New Zealand and Nursing Council of New Zealand. Pharmacists and nurses: roles and responsibilities. Wellington: Pharmacy Council of New Zealand and Nursing Council of New Zealand. [cited 2020 June 22]. Available from: https://www.pharmacycouncil.org.nz/dnn_uploads/Documents/standardsguidelines/Pharmacy%20Council%20_%20Nursing%20Council%20-%20Joint%20Statement%20-%20Oct%202018.pdf?ver=2018-10-09-195032-647&timestamp=1539114742359

[34]  Ministry of Health. Patient portals. Wellington: Ministry of Health; 2016. [cited 2020 July 20]. Available from: https://www.health.govt.nz/our-work/digital-health/other-digital-health-initiatives/patient-portals

[35]  HealthPathways Community. What is HealthPathways? Christchurch: HealthPathways Community, Canterbury District Health Board, and Streamliners NZ; 2020. [cited 2020 July 11]. Available from: https://www.healthpathwayscommunity.org/About

[36]  Health Navigator Editorial Team. Acute kidney injury. Wellington: Health Navigator Charitable Trust; 2020. [cited 2020 June 20]. Available from: https://www.healthnavigator.org.nz/health-a-z/k/kidney-acute-kidney-injury/

[37]  Kidney Health New Zealand. Information on kidney disease. Christchurch: Publisher; 2015. [cited 2020 June 20]. Available from: https://www.kidney.health.nz/Patient-Information/Information-on-Kidney-Disease/